亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Tbx Genes Regulate Cell Cycle Partially Through Control of N-Myc Transcription

技術應用
Potential therapies can be developed for the following by using T-box genes to control N-myc: Cancer treatments. Stem cell therapies to treat chronic and acute diseases. Genetic disorders involving T-box genes.
詳細技術說明
Scientists at UC San Diego have discovered that T-box transcription factors, particularly Tbx2 and Tbx20, can regulate the role of N-myc in cells that are dependent on N-myc expression. The technology demonstrates that the induction or repression of T-box genes can regulate N-myc which, in turn, will be able to affect major developments in the cell, particularly the cell’s proliferation, cell cycle, and differentiation. Cells that are dependent on N-myc expression include many cellular types implicated in development, such as certain cancers and stem cells.
*Abstract
The N-myc family of genes play a crucial role in the human body and is required for the growth and development of multiple organs, including the heart. The overexpression and amplification of N-myc is associated with a variety of tumors, most notably neuroblastomas and other childhood tumors. Despite its clinical relevance, little, if anything, is known as to which genes control expression of N-myc in vivo. The technology presented here provides evidence that N-myc expression can be regulated with T-box transcription factors (Tbx). T-box refers to a group of transcription factors that are expressed in a wide variety of tissue types and are involved in the development of diverse organs and tissues, particularly in the limbs and the heart. T-box genes also regulate patterning and cell fate, cell survival, and/or proliferation. Mutations in T-box genes are the cause of several congenital diseases and are implicated in cancer.
*IP Issue Date
Jul 19, 2011
*Principal Investigation

Name: Chen-Leng Cai

Department:


Name: Ju Chen

Department:


Name: Sylvia Evans

Department:


Name: Michael Rosenfeld

Department:


Name: Wenlai Zhou

Department:

附加資料
Patent Number: US7625874B2
Application Number: US2007734267A
Inventor: Evans, Sylvia | Chen, Ju | Cai, Chenleng | Zhou, Wenlai | Rosenfeld, Michael G
Priority Date: 11 Apr 2006
Priority Number: US7625874B2
Application Date: 11 Apr 2007
Publication Date: 1 Dec 2009
IPC Current: A61K004800 | C07H002102 | C07H002104 | C12N001563
US Class: 514044R | 514044 | 4353201 | 5360231 | 5360245
Assignee Applicant: The Regents of the University of California
Title: Compositions and methods for treating diseases associated with T-box and N-Myc
Usefulness: Compositions and methods for treating diseases associated with T-box and N-Myc
Summary: The method is useful in identifying a candidate N-Myc or Tbx2 upregulating compound or in treating cancer or heart disease (claimed).
Novelty: Identifying a candidate N-Myc or Tbx2 upregulating compound by contacting Tbx2 or Tbx20 with a known compound that binds Tbx2 or Tbx20 to form an assay mixture and determining the ability of the test compound to interact with Tbx2 or Tbx20
主要類別
診斷/治療
細分類別
癌症/腫瘤
申請號碼
7981615
其他

Intellectual Property Info

U.S. patent application filed 11-Apr-2007, published on 11-Oct-2007 (2007/0238692).


Related Materials



Tech ID/UC Case

19600/2005-223-0


Related Cases

2005-223-0

國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備